CureVac’s mRNA vaccine is being tested to assess its safety and efficacy in adults of various ages. The trials, which are expected to involve more than 35,000 participants, are taking place in Europe and Latin America.
“With the start of the pivotal Phase 2b/3 study, we have reached another important milestone in the development of our vaccine candidate, CVnCoV,” CureVac CEO Franz-Werner Haas, PhD, said in a news release. “The clinical safety and immunogenicity data achieved to date look promising and we are hopeful that this trial will continue to demonstrate the impact of mRNA technology and our vaccine to prevent COVID-19, and to help defeat this pandemic.”
More articles on COVID-19 vaccines:
US buys 100M more doses of Moderna vaccine
Cardinal Health to distribute COVID-19 vaccines in Ohio
‘Hope on the horizon’: Dr. Maggie Hagan discusses first days of vaccination at Ascension Via Christi
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
